{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:06:27Z","timestamp":1771603587313,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T05:33:54Z","timestamp":1657949634000},"page":"853-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments"],"prefix":"10.1016","volume":"22","author":[{"given":"Nicolas","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeeb","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen","family":"Yesil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-3058","authenticated-orcid":false,"given":"Daniel","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-4591","authenticated-orcid":false,"suffix":"III","given":"Homer","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2022.07.001_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"10.1016\/j.clml.2022.07.001_bib0002","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2022.07.001_bib0003","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification and management of myeloma precursor disease","volume":"19","author":"Agarwal","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2022.07.001_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2022.07.001_bib0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2022.07.001_bib0006","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2022.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2022.07.001_bib0008","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2022.07.001_bib0009","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2022.07.001_bib0010","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.103085","article-title":"A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma","volume":"99","author":"Korde","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2022.07.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without Lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial","volume":"4","author":"Nooka","year":"2018","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.clml.2022.07.001_bib0012","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.202491499","article-title":"T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells","volume":"99","author":"Dhodapkar","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.clml.2022.07.001_bib0013","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.clml.2022.07.001_bib0014","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2022.07.001_bib0015","doi-asserted-by":"crossref","first-page":"e98259","DOI":"10.1172\/jci.insight.98259","article-title":"Antigen-mediated regulation in monoclonal gammopathies and myeloma","volume":"3","author":"Nair","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.clml.2022.07.001_bib0016","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.clml.2022.07.001_bib0017","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"21","key":"10.1016\/j.clml.2022.07.001_bib0018","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2022.07.001_bib0019","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.clml.2022.07.001_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"7339","key":"10.1016\/j.clml.2022.07.001_bib0021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clml.2022.07.001_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clml.2022.07.001_bib0023","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1158\/1055-9965.EPI-07-2649","article-title":"Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility","volume":"17","author":"Ahmann","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.clml.2022.07.001_bib0024","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1073\/pnas.0914213107","article-title":"Seromic profiling of ovarian and pancreatic cancer","volume":"107","author":"Gnjatic","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2022.07.001_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-60327-811-9_2","article-title":"Autoantibodies against cancer antigens","volume":"520","author":"Gnjatic","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.clml.2022.07.001_bib0026","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.clml.2022.07.001_bib0027","doi-asserted-by":"crossref","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clml.2022.07.001_bib0028","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","article-title":"Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology","volume":"10","author":"Sattlecker","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.clml.2022.07.001_bib0029","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.4260","article-title":"High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer","volume":"231","author":"Emerson","year":"2013","journal-title":"J Pathol"},{"issue":"19","key":"10.1016\/j.clml.2022.07.001_bib0030","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2022.07.001_bib0031","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2008-02-133751","article-title":"Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2022.07.001_bib0032","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2006-08-042374","article-title":"Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2022.07.001_bib0033","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2141.2006.06052.x","article-title":"Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status","volume":"133","author":"Yeh","year":"2006","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2022.07.001_bib0034","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.exphem.2014.03.005","article-title":"Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro","volume":"42","author":"Bolomsky","year":"2014","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.clml.2022.07.001_bib0035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/cimm.1996.0064","article-title":"Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells","volume":"168","author":"Kang","year":"1996","journal-title":"Cell Immunol"},{"key":"10.1016\/j.clml.2022.07.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/580135","article-title":"TNF alpha mediated IL-6 secretion is regulated by JAK\/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells","volume":"2013","author":"Lee","year":"2013","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.clml.2022.07.001_bib0037","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.159.5.2212","article-title":"IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade","volume":"159","author":"Ogata","year":"1997","journal-title":"J Immunol"},{"issue":"7-8","key":"10.1016\/j.clml.2022.07.001_bib0038","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1034\/j.1600-0463.2003.11107812.x","article-title":"Against the self: dendritic cells versus cancer","volume":"111","author":"Cho","year":"2003","journal-title":"Apmis"},{"issue":"10","key":"10.1016\/j.clml.2022.07.001_bib0039","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2401146","article-title":"CD57+\/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis","volume":"12","author":"Van den Hove","year":"1998","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2022.07.001_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.clml.2022.07.001_bib0041","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s002770050397","article-title":"Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot","volume":"76","author":"Van den Hove","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.07.001_bib0042","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3389\/fimmu.2019.01844","article-title":"Maintenance of functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite controllers","volume":"10","author":"Phetsouphanh","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clml.2022.07.001_bib0043","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1038\/s41598-018-21389-8","article-title":"STAT3 regulates cytotoxicity of human CD57+ CD4+ T cells in blood and lymphoid follicles","volume":"8","author":"Alshekaili","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.clml.2022.07.001_bib0044","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/eji.202048626","article-title":"CD8(+) CD73(+) T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue","volume":"50","author":"Panigrahi","year":"2020","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.clml.2022.07.001_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12967-020-02285-0","article-title":"Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients","volume":"18","author":"Capone","year":"2020","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.clml.2022.07.001_bib0046","doi-asserted-by":"crossref","first-page":"e26246","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.clml.2022.07.001_bib0047","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00109-012-0991-z","article-title":"Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states","volume":"91","author":"Longhi","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.clml.2022.07.001_bib0048","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:21Z","timestamp":1761871221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002208"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}